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Purpose of the Review 
There is now good evidence in humans that a chronic systemic inflammatory response 
results in the cardinal features of cancer cachexia, principally the progressive loss of weight 
(in particular lean tissue).  This review examines the role of recent simple objective systemic 
inflammation-based scores in predicting reduction of nutritional status and survival.   
Recent findings 
The most common measure of the systemic inflammatory response in cancer patients 
has been an elevated C-reactive protein concentration.  This has now been included in recent 
definitions of cancer cachexia.  There are also recent systemic inflammation-based scores, the 
Glasgow Prognostic Score, Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte ratio 
which have been shown to have prognostic value in cancer patients.  These scores, in 
particular the Glasgow Prognostic Score, enable identification of patients who are or likely to 
develop cachexia, have a poor response to treatment and who are likely to have poor survival. 
Summary 
 A chronic systemic inflammatory response is clearly implicated in the progressive 
nutritional and functional decline of the cancer patient and their subsequent poor outcome.  
Systemic inflammation-based prognostic scores not only identify patients at risk but also 
provide well defined therapeutic targets for future clinical trials targeting nutritional decline.   
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Introduction 
The process of nutritional and functional decline in the patient with cancer is so 
common that is often accepted as part of cancer treatment and the disease itself.  The clear link 
between weight loss, poor performance status, poor response to treatment and poor prognosis 
is probably due to the preferential loss of skeletal muscle.  It has been suggested that the loss 
of adipose tissue accounts for the majority of the weight loss, but the loss of muscle for most 
of the morbidity and mortality [1, 2].  
However, the degree of weight loss that is prognostic is not well defined and 
performance status is recognised to be subjective and therefore their reliability has been 
questioned [1, 2].  Moreover, they do not provide objective therapeutic targets.  There is now 
good consistent evidence that the presence of a systemic inflammatory response is associated 
with increased weight loss, an elevated resting energy expenditure, loss of lean tissue and 
functional decline.  Furthermore, the use of anti-inflammatory agents is associated with 
moderation of weight loss and the maintenance of performance status and quality of life in 
patients with advanced cancer [3, 4]. 
 
Measurement of the systemic inflammatory response 
The basis of the systemic response in cancer patients is not clear, it may result from a 
non specific response secondary to tumour hypoxia/ necrosis or local tissue damage.  
Nevertheless, host responses to such systemic inflammation are myriad.  These include 
alterations in neuroendocrine metabolism including the endocrine hormones, haematopoietic 
changes including the interleukins, interferons and the haematopoetic growth factors and acute 
phase proteins [5].  The liver, in particular hepatocytes, are central to the elaboration of the 
systemic inflammatory response since they are stimulated to synthesise and release into the 
systemic circulation a variety of acute phase proteins, such as C-reactive protein, which 
 4 
initiate or sustain the systemic inflammatory response.  C-reactive protein, due to its 
sensitivity, specificity and reproducibility of analysis in hospital laboratories, is most 
commonly used to assess the magnitude (whether acute or chronic) of the systemic 
inflammatory response.  Recently, Marsik and coworkers [6] reported the relationship between 
C-reactive protein and all cause mortality in approximately 270,000 patients admitted to 
hospital.  There was with increasing C-reactive protein concentrations from normal (<5mg/l) 
to highly elevated (>80mg/l) there was a 3.3 fold increase in the risk of all cause mortality. 
The relation of CRP to cancer death was stronger than to vascular death and there was a 22.8 
fold increase in cancer mortality in those patients with highly elevated C-reactive protein 
concentrations (>80mg/l).  Indeed, the magnitude of the increase in C-reactive protein 
concentrations have been shown to be associated with poorer survival in cancer patients, 
particularly in patients with advanced disease, independent of tumour stage [3].  There has 
also been some work in primary operable cancer which has shown that the systemic 
inflammatory response, as evidenced by an elevated C-reactive protein concentration, has 
prognostic value in gastro-oesophageal [7], urinary bladder [8], pancreas [9], renal [10] and 
non-small cell lung [11] cancers, independent of tumour stage.  Also, a number of studies 
carried out in primary operable colorectal cancer have highlighted the independent prognostic 
value of an elevated C-reactive protein concentration [3].   
 It is of interest that in patients with cancer as C-reactive protein increases albumin 
falls and this relationship is similar across different tumour types [3].  Also, that albumin 
concentrations reflect both systemic inflammation and the amount of lean tissue [3].  
Therefore, the prognostic value of the combination of an elevated C-reactive protein 
concentration (>10mg/l) and hypoalbuminaemia (<35g/l) was examined [12], in 161 patients 
with inoperable non-small cell lung cancer.  On multivariate survival analysis, this 
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combination (HR 1.70, 95% CI 1.23–2.35, P<0.001) compared favourably with the clinical 
standard combination of stage and performance status (HR 1.48, 95% CI 1.12–1.95, P=0.006). 
This work resulted in the combination of C-reactive protein and albumin into a 
prognostic score (0, 1, 2).  This score, now termed the Glasgow Prognostic Score (GPS), was 
defined as follows; patients with both an elevated C-reactive protein (>10 mg/ l) and 
hypoalbuminaemia (<35 g/ l) were allocated a score of 2.  Patients in whom only one of these 
biochemical abnormalities was present were allocated a score of 1.  Patients in whom neither 
of these abnormalities was present were allocated a score of 0.  However, the score of 1 was 
most commonly due to an elevated C-reactive protein (33 out of 35 patients) emphasising the 
inflammatory basis of the GPS [12].  This inflammation based prognostic score (Table 1) has 
much to commend it since it has value independent of tumour stage, is simple to measure, 
routinely available and well standardised world-wide. 
 
The relationship between inflammation based scores, nutritional status and survival in 
patients with cancer 
The prognostic value of the GPS has been evaluated further in a variety of cancers 
including non-small cell lung cancer, breast cancer, gastro-oesophageal cancer, pancreatic 
cancer, renal cancer and colorectal cancer [13-26, Table 2].  These studies demonstrated that 
the prognostic value of the GPS was the independent of tumour stage and conventional scoring 
systems, superior to performance status and independent of treatment modalities.  Moreover, 
consistent with the cachexia derivation of the systemic inflammation-based GPS [3], it was 
directly associated with elevated cytokine and adipokine concentrations [22, 24], biochemical 
disturbance [21], the loss of weight and lean tissue, loss of performance status [21, 22, 24].  
More recently, the prognostic value of the neutrophil lymphocyte ratio (NLR) has been 
shown to have independent prognostic value in a variety of cancers including lung cancer, 
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gastric cancer, pancreatic cancer, colorectal cancer, colorectal liver metastases, 
cholangiocarcinoma and ovarian cancer [27-34, Table 3].  Also, the platelet lymphocyte ratio 
(PLR) has recently been shown to have independent prognostic value in patients undergoing 
potentially curative resection for pancreatic cancer [35, Table 3].  These studies demonstrated 
that the prognostic value of the NLR or the PLR was the independent of tumour stage and 
conventional scoring systems and independent of treatment modalities. 
 Recently, Leitch and coworkers [20] compared the the prognostic value of the GPS and 
components of the differential white cell count, including the NLR, in patients with either 
primary operable colorectal cancer (n=149) or synchronous unresectable liver metastases 
(n=84).  The GPS was a superior predictor of cancer specific survival compared with white 
cell components of the systemic inflammatory response including the NLR. 
 Recent reviews on the etiology of cancer cachexia have recognised the importance of 
systemic inflammation and have proposed a measure of systemic inflammation (elevated C-
reactive protein) in their definitions of cancer cachexia [1, 2].  However, such definitions also 
include highly variable clinical measures such as weight loss, fat free mass and food intake.  In 
contrast, the GPS is a simple objective measure that reflects cachexia and reliably predicts 
outcome in cancer patients.  Therefore, the GPS may be more suitable measure for the clinical 
definition of cancer cachexia..  
 
Conclusion 
Therefore, it can be concluded that markers of the systemic inflammatory response, in 
particular the GPS, is a reliable tumour stage independent prognostic factor in patients with 
cancer.  Moreover, that a measure of the systemic inflammatory response (GPS) be included, 
in addition or in preference to the current definitions of cachexia [1, 2], with tumour staging as 
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part of the routine assessment of all cancer patients.  As a consequence this will highlight the 
need not only to treat the tumour but also the systemic inflammatory response. 
 Further work is required to establish the value of measures of the systemic 
inflammatory response as stratification factors and selection criteria in randomised trials and 
as therapeutic targets in patients with cancer. 
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Table 1.  An inflammation-based prognostic score, the Glasgow Prognostic Score [3] 
 
Biochemical Characteristics Score 
C-reactive protein <10mg/l and albumin >35g/l 0 
C-reactive protein <10mg/l and albumin <35g/l 0 
C-reactive protein >10mg/l  1 
C-reactive protein >10mg/l and albumin <35g/l 2 
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Table 2.  Systemic inflammatory response, as evidenced by the GPS, as a prognostic factor in patients with cancer [14-27]. 
Study Tumour type n HR (p-value) Comments 
Forrest et al., [13]* Lung 109 1.70 (0.001) GPS independent of stage/ treatment and superior to ECOG-ps 
Al Murri et al., [14]* Breast 96 2.26 (<0.001) GPS independent of stage/ treatment 
Crumley et al., [15]* Gastro-oesophageal 258 1.51 (<0.001) GPS independent of stage/ treatment 
Crumley et al., [16]* Gastro-oesophageal  65 1.65 (<0.05) GPS independent of stage/ treatment and superior to ECOG-ps 
Glen et al., [17]* Pancreas 187 1.72 (<0.001) GPS independent of stage 
Ramsey et al., [18]* Renal 119 2.35 (<0.001) GPS independent of scoring systems 
McMillan et al., [19]* Colorectal 316 1.74 (<0.001) GPS independent of stage/ treatment 
Leitch et al., [20]*  Colorectal 233 2.08 (<0.001) GPS superior to WCC/ lymphocytes  
Brown et al., [21]* Lung and colorectal 50 Not reported GPS associated with weight loss, poor performance status and biochemical disturbance 
     
K-Korpacka et al., 
[22] 
Gastro-oesophageal 96 Not reported GPS associated with weight loss, transferrin, IL-1, IL-6, IL-8, TNF, VEGF-A and 
midkine concentrations 
Kobayashi et al., [23] Oesophageal 48 Not reported GPS independent of stage/ treatment and associated with toxicity 
Kerem et al., [24] Gastric 60 Not reported GPS associated with weight loss, ghrelin, resistin, adiponectin and leptin 
Ishizuka et al., [25] Colorectal 315 1.53 (p<0.01) GPS independent of stage/ treatment 
Read et al., [26] Colorectal 84 2.27 (p<0.05) GPS independent of stage/ treatment 
Sharma et al., [27] Colorectal 84 Not reported GPS independent of stage/ treatment and associated with toxicity 
Sharma et al., [28] Ovarian 154 1.68 (<0.01) GPS independent of stage/ treatment 
* studies from the Glasgow group, HR hazard ratio for incremental change of GPS. 
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Table 3.  Systemic inflammatory response, as evidenced by the Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio, as a prognostic 
factor in patients with cancer [28-35] 
 
Study Tumour type n HR (p-value) Comments 
Yamanaka et al., [29]* Gastric 1220 1.52 (<0.001) NLR independent of stage/ treatment 
Walsh et al., [30]* Colorectal 230 Not reported NLR predicted cancer survival 
Malik et al., [31]* Colorectal liver 687 1.73 (<0.001) NLR independent of stage/ treatment 
Halazun et al., [32]* Colorectal liver 440 2.26 (<0.001) NLR independent of stage/ treatment 
Gomez et al., [33]* Cholangiocarcinoma 27 1.78 (<0.01) NLR independent of stage/ treatment 
Cho et al., [34]* Ovarian 192 8.42 (<0.05) NLR independent of stage/ treatment 
     
Smith et al., [35]** Pancreatic 110 1.004 (p<0.01) PLR independent of stage/ treatment 
     
* Neutrophil Lymphocyte Ratio prognostic studies, ** Platelet Lymphocyte Ratio prognostic studies, HR hazard ratio for incremental change of 
NLR or PLR.. 
 
